Recombinant Human LRIG3 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg2853
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human LRIG3 protein Asp28-Thr807 (Accession# Q6UXM1-1) with a rabbit Fc tag at the C-terminus. |
| GeneID | 121227 |
| Accession | Q6UXM1-1 |
| PredictedSize | 112.6 kDa |
| SDS-PAGE | 112-120 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
LRIG3, or leucine-rich repeats and immunoglobulin-like domains 3, is a member of the LRIG family of transmembrane proteins. LRIG3 is known to play a role in the regulation of growth factor receptor signaling, which includes receptor tyrosine and serine/threonine kinases. LRIG3 has been implicated in various biological processes, including the regulation of tumor growth and angiogenesis. It has been reported that LRIG3 can act as a tumor suppressor in glioblastoma multiforme (GBM), where it modulates the proliferation, migration, and invasion of glioma cells by targeting the EGFR and MET signaling pathways.
References:
1. Simion C, et al. (2014). Endocr Relat Cancer. 21(6):R431-43. 2. Peng C, et al. (2021). Front Oncol.11:621154.